Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
CE

NASDAQ · CERT

Certara, Inc.

Healthcare · Medical - Healthcare Information Services

$11.02

Down-$0.18 (-1.61%)

Updated Oct 31, 2026, 2:08 AM

SID Score

4.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.42B
P/E ratio
177.53
Dividend yield
0.00%
52-week range
$4.45 – $12.29
Volume
1.95M
Avg. volume
2.12M

Price performance · CERT

CERT price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

CERT closed at $11.02 after 21 trading sessions, up 17.74% for the selected period.

Last close
$11.02
Period change
+17.74%
Period low
$8.64
Period high
$11.48
Daily close
View OHLC price history
CERT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$11.07$11.19$10.645$11.021.95M
Oct 29, 2026$11.46$11.57$11.08$11.202.75M
Oct 28, 2026$10.84$11.73$10.84$11.482.37M
Oct 27, 2026$10.50$10.98$10.435$10.952.42M
Oct 26, 2026$10.20$10.625$10.0793$10.612.35M
Oct 23, 2026$9.95$10.37$9.835$10.332.06M
Oct 22, 2026$10.14$10.31$9.86$10.092.37M
Oct 21, 2026$9.67$10.2899$9.47$10.181.72M
Oct 20, 2026$9.50$9.85$9.37$9.7852.78M
Oct 19, 2026$9.37$9.50$9.255$9.451.5M
Oct 16, 2026$9.745$9.94$9.215$9.372.36M
Oct 15, 2026$9.39$9.701$9.25$9.661.66M
Oct 14, 2026$9.54$9.63$9.28$9.361.82M
Oct 13, 2026$9.30$9.90$9.26$9.602.91M
Oct 12, 2026$9.12$9.25$9.0044$9.241.52M
Oct 9, 2026$8.85$9.27$8.64$9.135.04M
Oct 8, 2026$8.895$8.955$8.58$8.644.13M
Oct 7, 2026$9.17$9.305$8.93$8.963.43M
Oct 6, 2026$10.07$10.19$9.1902$9.273.95M
Oct 5, 2026$9.36$10.07$9.28$10.072.94M
Oct 2, 2026$9.41$9.45$9.045$9.362.65M

Latest CERT news

The latest Smart Investors Daily articles mentioning CERT.

Stock researchCompany · Overview

CERT research

Overview

Company profile and research snapshot.

Company profile

Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$13.00
Implied upside
—
Analysts
—
CERT recent ratings
DateFirmRatingTarget
Oct 16, 2026KeybancOverweight—
Oct 13, 2026TD CowenBuy—
Oct 7, 2026BarclaysEqual-Weight—
Sep 30, 2026UBSNeutral—
Aug 5, 2026BarclaysEqual-Weight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 26, 2026

Certara to Report Third Quarter 2026 Financial Results on November 5th, 2026

RADNOR, Pa., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2026 before market open on Thursday, November 5th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET. To listen by phone, investors may dial 800-715-9871 (646-307-1963 for international callers) and enter access code 2208277. The live webcast wil

Yahoo · Oct 23, 2026

Certara (CERT) Stock May Trade Above Fair Value On Its 75% Slump

Certara has seen its share price move around in recent years, which puts fresh attention on a simple question for anyone looking at the stock today. Is the current US$10.33 price broadly aligned with what the business may realistically produce in cash over time? Over the past 5 years the stock has fallen 75.0%, which puts the focus squarely on whether the future cash flows can justify even a partial recovery from here. The company relies on software and services that turn drug development...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By